US Patent

US12296047 — Manufacturing of bupivacaine multivesicular liposomes

Method of Use · Assigned to Pacira Pharmaceuticals Inc · Expires 2041-01-22 · 15y remaining

Vulnerability score 75/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects a method for manufacturing bupivacaine multivesicular liposomes using a commercial process with a large particle diameter span.

USPTO Abstract

Embodiments of the present application relate to compositions bupivacaine multivesicular liposomes (MVLs) prepared by a commercial manufacturing process with large particle diameter span.

Drugs covered by this patent

Bupivacaine Hydrochloride And Epinephrine (BUPIVACAINE) · Innocoll

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-4184`	—	Bupivacaine Hydrochloride And Epinephrine
`U-4184`	—	Bupivacaine Hydrochloride And Epinephrine

Patent Metadata

Patent number: US12296047
Jurisdiction: US
Classification: Method of Use
Expires: 2041-01-22
Drug substance claim: No
Drug product claim: Yes
Assignee: Pacira Pharmaceuticals Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.